J&J consumer sales increase of 6% in third quarter reflects international gains.
This article was originally published in The Tan Sheet
J&J CITES INTERNATIONAL BUSINESS FOR 6% GAIN IN CONSUMER SALES to $1.46 bil. during the third quarter ended Sept. 30. International consumer sales rose 12.7% during the period to $744 mil. due largely to the improved performance of the company's business in Brazil, J&J explained in an Oct. 19 release
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.